Introduction
The PSMA-targeted [ 68 Ga]Ga-HBED-CC (PSMA-11) radiopharmaceutical has been shown to be quite useful in imaging patients with prostate cancer to define the location and extent of disease [1] [2] . However, despite its fairly extensive human use of [ 68 Ga]Ga-HBED-CC, until recently no estimates of the human radiation dosimetry for [ 68 Ga]Ga-HBED-CC were available in the published literature. Those recently published data [3, 4] represent findings in a very limited number of subjects, in one case only four subjects [3] , and the other case, five subjects who received a concurrent dosing with furosemide [4] . To Independently assess [ 68 Ga]Ga-HBED-CC (PSMA-11) dosimetry, we have evaluated the radiopharmaceutical's biodistribution and pharmacokinetics with serial PET imaging following intravenous administration to nine prostate cancer patients in whom 11 C-acetate PET/CT exams had been clinically performed under Expanded Access IND 118,204 to assess disease recurrence.
Materials and Methods
Our use of [ 68 due to suspected recurrence of prostate cancer that had previously been treated with surgery or radiation therapy (i.e., all subjects were prostate cancer patients presenting with "biochemical failure"). All subjects provided written informed consent prior to 4 administration of the [ 68 the exceptions of using only a 5-minute reaction time, and the substitution of HBED-CC (PSMA-11) for DOTA-NOC [5] . Pre-release product quality control procedures included:
half-life measurement for confirmation of radionuclidic identity; pH measurement; ITLC assessment of radiochemical purity; endotoxin testing; and a bubble point measurement to confirm the integrity of the single-use sterile 0.2-µm filter employed for terminal product sterilization. The ITLC determination of radiochemical purity employed ITLC-SG strips developed with 1:1 MeOH:1M NH 4 OAc to quantify colloidal 68 Ga-hydroxide plus ionic 68 Ga, both of which remain at or near the origin while the [ 68 Ga]Ga-HBED-CC product migrates near the solvent front. Retrospective analysis of each production batch 5 included sterility testing, and measurement of 68 Ge breakthrough levels in the final product [5] .
PET/CT Imaging and Image Analysis
Imaging was performed using a Siemens mCT extended FOV time-of-flight PET/CT (128 slice) camera. Following a low-dose pelvis-to-head CT scan for attenuation correction, the radiopharmaceutical was administered intravenously with the patient's pelvis in the PET field-of-view for a list-mode acquisition from 0-10 minutes, followed by a wholebody (pelvis to head) PET acquisition starting at 15-minutes post-injection. An image of the pelvis was again collected at 40-minutes, then the patient removed from the camera and urine collected. The patient then returned to the PET/CT camera for a second lowdose (attenuation correction only) CT scan, followed by whole-body (pelvis-to-head) PET acquisitions at 60-minutes and 90-minutes, with a final PET image of the pelvis collected at 115 minutes. Again the patient was removed from the camera and directed to void his bladder with collection of the excreted urine. The volume of the collected urine samples was measured, and the excreted radioactivity quantified by dose calibrator assay of a 20-mL sample. PET images were reconstructed using both filtered back-projection radioactivity was assumed to be uniformly distributed in the remaining body volume.
Results and Discussion
The [ 68 Ga]Ga-HBED-CC (PSMA-11) radiopharmaceutical has been shown to be useful in the detection of tumor recurrence in prostate cancer patients previously treated with prostatectomy or radiation therapy [1, 2] , with lesion detectability appearing to be better than we can achieve with [ 11 C]acetate PET/CT. [ 68 Ga]Ga-HBED-CC (PSMA-11) has a relatively low molecular weight (1014 g/mole), and targets the cell surface prostatespecific membrane antigen (PSMA) with the urea fragment of the Glu-urea-Lys(Ahx)-HBED-CC conjugate [9] . The 68 Ga 3+ ion is bound with high affinity in an octahedral N 2 O 4 coordination sphere by the two phenolate O, two amino-acetate carboxylate O, and the two amino N donor atoms of the HBED chelator [9] [10] [11] [12] .
Radiochemical purity of the [ 68 Ga]Ga-HBED-CC (PSMA-11) averaged 98.9 ± 0.5% (n = 9), with 68 Ge breakthrough levels in the final product averaging 8. The PET/CT biodistribution findings for [ 68 Ga]Ga-HBED-CC are shown in Table 1 
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Figure 1. Example of PET images (right) and fused PET/CT images (left)
obtained with 68 Ga-HBED-CC (PSMA-11) (top) and 11 C-acetate (bottom). The 11 C acetate image was obtained 48-days prior to 68 Ga imaging. Serum PSA was 1.7 ng/mL at the time of the acetate study. The red arrows indicates PSMA-avid retroperitoneal lymph nodes that are not acetate-avid (yellow arrows). The acetate PET image was reconstructed from data collected at 10 minutes post-injection. The 68 Ga image was reconstructed from data collected at 15 minutes post-injection. Lymph node uptake in the 68 Ga-images showed slight increase with time (SUV mean values of 6.0, 7.8, and 8.8 (lymph node A) and 5.3, 7.3 and 9.6 (lymph node B) in images collected at 15, 60, and 90-minutes post-injection, respectively).
Figure 2. Additional example of PET images (right) and fused PET/CT images (left)
obtained with 68 Ga-HBED-CC (PSMA-11) (top) and 11 C-acetate (bottom). The 11 C acetate image was obtained 23-days prior to 68 Ga imaging. Serum PSA was 11.1 ng/mL at the time of the acetate study. Red arrow indicates PSMA-avid bone metastasis in right ilium that was not seen on the 11 C-acetate exam. Ureters are noted on the PSMA study.
The acetate image was reconstructed from data collected at 10 minutes post-injection, and the 68 Ga image reconstructed from data collected at 15 minutes postinjection. Tumor uptake in the 68 
